​

Amgen (AMGN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AMGN Stock Forecast

Amgen (AMGN) stock forecast, based on 41 Wall Street analysts, predicts a 12-month average price target of $415.58, with a high of $500.00 and a low of $230.00. This represents a -9.71% decline from the last price of $460.28.

$200 $260 $320 $380 $440 $500 High: $500 Avg: $415.58 Low: $230 Last Closed Price: $460.28

AMGN Stock Rating

Amgen stock's rating consensus is Buy, based on 41 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 21 Buy (51.22%), 17 Hold (41.46%), 3 Sell (7.32%), and 0 Strong Sell (0.00%).

Buy
Total 41 0 3 17 21 Strong Sell Sell Hold Buy Strong Buy

AMGN Price Target Upside V Benchmarks

TypeNameUpside
StockAmgen-9.71%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks2.95%

Price Target Trends

1M3M12M
# Anlaysts142565
Avg Price Target$427.57$422.40$384.46
Last Closing Price$460.28$460.28$460.28
Upside/Downside-7.11%-8.23%-16.47%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 2648173234
Oct, 2648173234
Sep, 26410162234
Aug, 26410172134
Jul, 26410172134
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 04, 2026Carter GouldCantor Fitzgerald$465.00$473.82-1.86%1.03%
Nov 04, 2026Courtney BreenBernstein$400.00$473.04-15.44%-13.10%
Nov 04, 2026Luca IssiRBC Capital$470.00$472.83-0.60%2.11%
Nov 04, 2026Greg RenzaTruist Financial$398.00$469.85-15.29%-13.53%
Nov 04, 2026Gary NachmanCanaccord Genuity$440.00$461.26-4.61%-4.41%
Nov 04, 2026Mohit BansalWells Fargo$460.00$461.26-0.27%-0.06%
Oct 23, 2026Oppenheimer$480.00$447.287.32%4.28%
Oct 21, 2026Barclays$400.00$438.94-8.87%-13.10%
Oct 13, 2026Vamil DivanGuggenheim$378.00$417.57-9.48%-17.88%
Oct 12, 2026BMO Capital$415.00$415.80-0.19%-9.84%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 04, 2026Cantor FitzgeraldNeutralNeutralhold
Nov 04, 2026Cowen & Co.BuyBuyhold
Nov 04, 2026BernsteinMarket PerformMarket Performhold
Nov 04, 2026RBC CapitalOutperformOutperformhold
Nov 04, 2026William BlairOutperformOutperformhold
Oct 23, 2026OppenheimerOutperformOutperformhold
Oct 13, 2026GuggenheimNeutralNeutralhold
Oct 08, 2026RBC CapitalOutperformOutperformhold
Oct 05, 2026Cantor FitzgeraldNeutralNeutralhold
Sep 28, 2026ScotiabankOutperformOutperformhold

Financial Forecast

EPS Forecast

$5 $11 $17 $23 $29 $35 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.34$12.18$12.56$7.62$14.33---
Avg Forecast$16.82$17.68$18.56$19.59$21.01$21.45$22.22$22.74
High Forecast$17.52$18.41$18.98$19.86$22.39$30.68$31.07$23.91
Low Forecast$16.19$16.80$18.23$19.25$19.62$10.68$16.86$21.04
Surprise %-38.53%-31.11%-32.33%-61.10%-31.79%---

Revenue Forecast

$25B $28B $31B $34B $37B $40B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$25.98B$26.32B$28.19B$33.42B$36.75B---
Avg Forecast$26.00B$26.17B$28.12B$33.20B$34.61B$35.07B$35.60B$36.33B
High Forecast$26.84B$27.00B$28.29B$33.48B$35.96B$35.08B$35.66B$37.75B
Low Forecast$25.25B$25.17B$27.97B$32.91B$32.45B$35.06B$35.55B$34.23B
Surprise %-0.09%0.58%0.26%0.68%6.18%---

Net Income Forecast

$0 $4B $8B $12B $16B $20B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$5.89B$6.55B$6.72B$4.09B$7.71B---
Avg Forecast$5.71B$6.49B$6.72B$10.52B$11.30B$7.13B$12.89B$12.24B
High Forecast$6.85B$7.79B$8.06B$10.68B$12.05B$16.50B$16.71B$12.86B
Low Forecast$4.56B$5.19B$5.37B$10.36B$10.56B$5.74B$9.07B$11.32B
Surprise %3.29%0.90%--61.12%-31.77%---

AMGN Forecast FAQ

Is Amgen stock a buy?

Amgen stock has a consensus rating of Buy, based on 41 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 21 Buy, 17 Hold, 3 Sell, and 0 Strong Sell, reflecting a consensus that Amgen is a favorable investment for most analysts.

What is Amgen's price target?

Amgen's price target, set by 41 Wall Street analysts, averages $415.58 over the next 12 months. The price target range spans from $230 at the low end to $500 at the high end, suggesting a potential -9.71% change from the previous closing price of $460.28.

How does Amgen stock forecast compare to its benchmarks?

Amgen's stock forecast shows a -9.71% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the drug manufacturers - general stocks industry (2.95%).

What is the breakdown of analyst ratings for Amgen over the past three months?

  • November 2026: 11.76% Strong Buy, 23.53% Buy, 50.00% Hold, 8.82% Sell, 5.88% Strong Sell.
  • October 2026: 11.76% Strong Buy, 23.53% Buy, 50.00% Hold, 8.82% Sell, 5.88% Strong Sell.
  • September 2026: 11.76% Strong Buy, 29.41% Buy, 47.06% Hold, 5.88% Sell, 5.88% Strong Sell.

What is Amgen’s EPS forecast?

Amgen's average annual EPS forecast for its fiscal year ending in December 2026 is $21.45, marking a 49.69% increase from the reported $14.33 in 2025. Estimates for the following years are $22.22 in 2027, and $22.74 in 2028.

What is Amgen’s revenue forecast?

Amgen's average annual revenue forecast for its fiscal year ending in December 2026 is $35.07B, reflecting a -4.57% decrease from the reported $36.75B in 2025. The forecast for 2027 is $35.6B, and $36.33B for 2028.

What is Amgen’s net income forecast?

Amgen's net income forecast for the fiscal year ending in December 2026 stands at $7.13B, representing a -7.56% decrease from the reported $7.71B in 2025. Projections indicate $12.89B in 2027, and $12.24B in 2028.